文献速递类风湿关节炎

类风湿关节炎疼痛遗传风险评分的开发与外部验证

Development and External Validation of a Genetic Risk Score for Pain in Rheumatoid Arthritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-09-11

研究在FORWARD队列(756例)中基于36个纤维肌痛相关SNP构建疼痛遗传风险评分,并在VARA队列(2176例)中外部验证。验证队列中纤维肌痛遗传风险评分最高四分位者基线疼痛较最低四分位者高0.55(95%CI 0.16-0.93,P=0.006),两种评分最高四分位者随访期间疼痛及疾病活动度更高。

要点

  • 基于36个纤维肌痛相关SNP的疼痛遗传风险评分在类风湿关节炎验证队列中与基线疼痛相关。
  • VARA队列中纤维肌痛遗传风险评分最高四分位者基线疼痛较最低四分位者高0.55(95%CI 0.16-0.93,P=0.006)。
  • 两种遗传风险评分最高四分位者随访期间疼痛及疾病活动度评分更高。

核心结论

  • 基于疼痛相关SNP的遗传风险评分与类风湿关节炎疼痛及疾病活动度相关,提示疼痛遗传风险可能在类风湿关节炎中具有临床影响,如达到缓解的可能性。

研究设计与样本

  • 研究纳入两个独立类风湿关节炎队列:FORWARD(美国国家风湿病数据库,训练数据集)和退伍军人事务部类风湿关节炎登记处(VARA,验证数据集)。
  • 在FORWARD中使用多变量线性回归估计横断面疼痛评分与36个纤维肌痛相关SNP的关系。
  • 将SNP等位基因求和并按回归系数加权,为两个队列每位参与者生成疼痛遗传风险评分。
  • 使用线性回归和广义估计方程确定该遗传风险评分、现有疼痛强度遗传风险评分与疼痛及自报疾病活动度的关系。

主要发现

  • 样本包括FORWARD的756例参与者(平均年龄56.8岁,89.4%女性)和VARA的2176例参与者(平均年龄64.3岁,11.0%女性),均有疼痛和基因分型数据。
  • 验证数据集VARA中纤维肌痛遗传风险评分最高四分位者较最低四分位者基线疼痛更多(+0.55,95%CI 0.16-0.93,P=0.006)。
  • 现有疼痛强度遗传风险评分也呈现相同模式。
  • VARA中两种遗传风险评分均处于最高四分位的参与者随访期间疼痛更多且疾病活动度评分更高。

关键数值与推荐

  • 纤维肌痛遗传风险评分最高四分位者较最低四分位者基线疼痛差异为+0.55(95%CI 0.16-0.93,P=0.006)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Several single-nucleotide polymorphisms (SNPs) have been associated with chronic pain syndromes. Our objective was to determine whether genetic variants are associated with pain and disease activity in rheumatoid arthritis (RA). METHODS: Participants were included from two independent RA cohorts: FORWARD (National Databank for Rheumatic Diseases, training data set) and the Veterans Affairs Rheumatoid Arthritis Registry (VARA; validation data set). Multivariable linear regression was used to estimate the relationship between cross-sectional pain scores and 36 fibromyalgia (FM)-associated SNPs in FORWARD. SNP alleles were summed and weighted by these regression coefficients to generate a genetic risk score (GRS) for pain for each participant in both cohorts. Linear regressions and generalized estimating equations were used to determine the relationship between this GRS, an existing pain intensity GRS, and pain and self-reported disease activity. RESULTS: The sample comprised 756 participants from FORWARD (mean age 56.8 years, 89.4% female) and 2,176 participants from VARA (mean age 64.3 years, 11.0% female) who had pain and genotyping data. Participants in the validation data set (VARA) with FM GRS in the highest quartile had more baseline pain than those in the lowest quartile (+0.55 [95% confidence interval 0.16-0.93], P = 0.006). This was also true for the existing pain intensity GRS. VARA participants in the highest quartile of both GRS had more pain throughout follow-up and higher disease activity scores. CONCLUSION: GRS based on pain-related SNPs were associated with RA pain and disease activity, suggesting that the genetic risk of pain may have clinical impacts in RA, such as the likelihood of achieving remission.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. McMenamin KJ, Riley TR, Wipfler K, et al. Development and External Validation of a Genetic Risk Score for Pain in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2025. PMID: 40583606. doi:10.1002/acr.25588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。